Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
human vacines & immunotherapeutics
;
17(9): 1-5, 2021.
Article
Dans Anglais
| LILACS, CONASS, ColecionaSUS, SES-SP, SESSP-IALPROD, SES-SP
| ID: biblio-1417874
ABSTRACT
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Vaccins contre la COVID-19
/
SARS-CoV-2
/
Immunité cellulaire
/
Antigènes
/
Neisseria meningitidis
langue:
Anglais
Texte intégral:
Human vacines & immunotherapeutics
Année:
2021
Type:
Article
Institution/Pays d'affiliation:
Animal Health Department, Embrapa Southern Region Animal Husbandry/BR
/
Department of Immunology/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS